Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Authors
Keywords
-
Journal
Molecular Cancer
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-07-06
DOI
10.1186/s12943-023-01805-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T cells: engineered immune cells to treat brain cancers and beyond
- (2023) Zoufang Huang et al. Molecular Cancer
- Tamoxifen evolution
- (2023) A. Howell et al. BRITISH JOURNAL OF CANCER
- Immunotherapy in breast cancer: an overview of current strategies and perspectives
- (2023) Véronique Debien et al. npj Breast Cancer
- Breast Cancer Vaccines: Disappointing or Promising?
- (2022) Si-Yuan Zhu et al. Frontiers in Immunology
- Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer
- (2022) Helena Čelešnik et al. Cancers
- Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
- (2022) Massimo Cristofanilli et al. CLINICAL CANCER RESEARCH
- Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
- (2022) Chiara Francavilla et al. Open Biology
- Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
- (2022) Nehad M. Ayoub et al. Frontiers in Pharmacology
- Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
- (2022) Pouya Safarzadeh Kozani et al. Frontiers in Immunology
- PARP inhibition in breast cancer: progress made and future hopes
- (2022) Nadine Tung et al. npj Breast Cancer
- Nanobody-based CAR-T cells for cancer immunotherapy
- (2022) Pouya Safarzadeh Kozani et al. Biomarker Research
- Carnosic acid attenuates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and its concomitant pathological consequences
- (2022) Prasenjit Manna et al. FOOD AND CHEMICAL TOXICOLOGY
- Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
- (2022) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
- (2022) Md. Mominur Rahman et al. MOLECULES
- CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?
- (2022) Pooria Safarzadeh Kozani et al. Frontiers of Medicine
- Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
- (2022) Jakub Wesolowski et al. Cancers
- PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
- (2022) Kunrui Zhu et al. Cells
- Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035
- (2022) Yizhen Li et al. Frontiers in Oncology
- Breast Cancer Statistics, 2022
- (2022) Angela N. Giaquinto et al. CA-A CANCER JOURNAL FOR CLINICIANS
- GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
- (2022) Hope S Rugo et al. Future Oncology
- Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness
- (2022) Raghuveer Kavarthapu et al. Frontiers in Endocrinology
- The Cellular and Molecular Immunotherapy in Prostate Cancer
- (2022) Anirban Goutam Mukherjee et al. Vaccines
- Current and future burden of breast cancer: Global statistics for 2020 and 2040
- (2022) Melina Arnold et al. BREAST
- Cellular and molecular basis of therapeutic approaches to breast cancer
- (2022) Mohamed El-Tanani et al. CELLULAR SIGNALLING
- Tremelimumab: First Approval
- (2022) Susan J. Keam DRUGS
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
- (2022) Stephen R D Johnston et al. LANCET ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
- (2022) Melani Luque et al. Cancers
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- An Overview of PARP Inhibitors for the Treatment of Breast Cancer
- (2021) Laura Cortesi et al. Targeted Oncology
- Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
- (2021) Julia Foldi et al. npj Breast Cancer
- Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
- (2021) Sara M. Tolaney et al. CLINICAL CANCER RESEARCH
- Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
- (2021) José M. Pérez-García et al. EUROPEAN JOURNAL OF CANCER
- AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
- (2021) Federica Martorana et al. Frontiers in Pharmacology
- Strategies for Dodging the Obstacles in CAR T Cell Therapy
- (2021) Pooria Safarzadeh Kozani et al. Frontiers in Oncology
- Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
- (2021) Maitri Kalra et al. npj Breast Cancer
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
- (2021) Ming Shen Dai et al. BREAST CANCER RESEARCH AND TREATMENT
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
- (2021) Lajos Pusztai et al. CANCER CELL
- Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis
- (2021) Zicong You et al. Cancer Cell International
- Estrogen receptor-α signaling in post-natal mammary development and breast cancers
- (2021) Mariam Rusidzé et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
- (2021) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.
- (2021) Snehal Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
- (2021) Saikat Ghosh et al. JOURNAL OF CONTROLLED RELEASE
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
- (2021) Ye Hu et al. Cancer Management and Research
- Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
- (2021) Raghuveer Kavarthapu et al. Cancers
- Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
- (2021) Yang Li et al. Frontiers in Bioengineering and Biotechnology
- Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
- (2021) Romualdo Barroso-Sousa et al. npj Breast Cancer
- Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
- (2021) Nicholas Turner et al. BREAST CANCER RESEARCH AND TREATMENT
- A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
- (2021) Sylvia Adams et al. CLINICAL CANCER RESEARCH
- U.S. FDA Drug Approvals for Breast Cancer — A Decade in Review
- (2021) Shaily Arora et al. CLINICAL CANCER RESEARCH
- Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation
- (2021) Anne Patsouris et al. EUROPEAN JOURNAL OF CANCER
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- (2021) Issam Makhoul et al. Oncotarget
- The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration
- (2021) Mariya Farooq et al. Cells
- Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
- (2021) Peter Lawrence Smith et al. Vaccines
- CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
- (2020) Michael R Migden et al. Future Oncology
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- (2020) Robert H Jones et al. LANCET ONCOLOGY
- Circumventing AKT-Associated Radioresistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capivasertib
- (2020) Liwei Lang et al. Cells
- Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
- (2020) Tommy A. Brown et al. BREAST CANCER RESEARCH AND TREATMENT
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
- (2020) Lillian M Smyth et al. CLINICAL CANCER RESEARCH
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
- (2020) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
- (2020) Miguel A. Ortega et al. Journal of Oncology
- Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer
- (2020) María Florencia Mercogliano et al. Frontiers in Oncology
- Tucatinib: First Approval
- (2020) Arnold Lee DRUGS
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects
- (2020) Yu Liu et al. Oncology Letters
- Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
- (2020) María G. C. Navarrete-Bernal et al. Frontiers in Oncology
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
- (2020) P.A. Fasching et al. ANNALS OF ONCOLOGY
- The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
- (2020) ATHINA STRAVODIMOU et al. ANTICANCER RESEARCH
- Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions
- (2020) Altaf Ahmad Shah et al. CURRENT DRUG METABOLISM
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
- (2020) Sara M. Tolaney et al. JAMA Oncology
- The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
- (2020) Maria Francesca Santolla et al. Cancers
- Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer
- (2020) Chong Shuai et al. Frontiers in Oncology
- Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
- (2020) Jesús Fuentes-Antrás et al. Frontiers in Oncology
- Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer
- (2020) Javier A. Menendez et al. Aging-US
- PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
- (2020) Daniela Miricescu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
- (2020) Laura Boyero et al. Cancers
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes
- (2019) Kan Yonemori et al. EUROPEAN JOURNAL OF CANCER
- BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
- (2019) N C Turner et al. ANNALS OF ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
- (2019) Aradhana Rani et al. Frontiers in Endocrinology
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
- (2019) M Oliveira et al. ANNALS OF ONCOLOGY
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
- (2019) Di (Maria) Jiang et al. Oncotarget
- Estrogen signaling: An emanating therapeutic target for breast cancer treatment
- (2019) Tanmay Saha et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
- (2019) Daniele Presti et al. Cancers
- Efficacy of PI3K inhibitors in advanced breast cancer
- (2019) B Verret et al. ANNALS OF ONCOLOGY
- A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
- (2019) Alice Y. Ho et al. CANCER
- FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
- (2019) Suparna Wedam et al. CLINICAL CANCER RESEARCH
- Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
- (2019) Sara A. Hurvitz et al. ONCOLOGIST
- Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
- (2019) John F.R. Robertson et al. CLINICAL CANCER RESEARCH
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
- (2019) Constantin N. Baxevanis et al. SEMINARS IN CANCER BIOLOGY
- FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
- (2018) Anand Shah et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Driving T-cell immunotherapy to solid tumors
- (2018) Ken Garber NATURE BIOTECHNOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
- (2018) Hitisha K. Patel et al. PHARMACOLOGY & THERAPEUTICS
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
- (2018) Cesar August Santa-Maria et al. Oncotarget
- Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?
- (2018) Kulmira Nurgali et al. Frontiers in Pharmacology
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Profile of abemaciclib and its potential in the treatment of breast cancer
- (2018) James M Martin et al. OncoTargets and Therapy
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients
- (2018) Kaitlin Rascon et al. ANNALS OF PHARMACOTHERAPY
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
- (2018) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- The Akt pathway in oncology therapy and beyond (Review)
- (2018) George Nitulescu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells
- (2017) Raghuveer Kavarthapu et al. Oncotarget
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
- (2017) Jung-Min Lee et al. Oncotarget
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- PD-1/PD-L1 Pathway in Breast Cancer
- (2017) Florian Schütz et al. Oncology Research and Treatment
- A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
- (2016) Steven A. Limentani et al. BREAST CANCER RESEARCH AND TREATMENT
- Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)
- (2016) J Balmana et al. CANCER RESEARCH
- Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data
- (2016) Neelima Vidula et al. Clinical Breast Cancer
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
- (2016) H. L. McArthur et al. CLINICAL CANCER RESEARCH
- Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
- (2016) K. B. Wisinski et al. CLINICAL CANCER RESEARCH
- Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
- (2016) Niloy Bhattacharjee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
- (2016) Zachary B Jenner et al. Future Oncology
- The development and use of the E75 (HER2 369–377) peptide vaccine
- (2016) Guy T Clifton et al. Future Oncology
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tremelimumab: research and clinical development
- (2016) Francisco Javier Ibarrondo et al. OncoTargets and Therapy
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
- (2015) Soo Youn Bae et al. BMC CANCER
- Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
- (2015) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
- (2015) Weimin Fan et al. Future Medicinal Chemistry
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
- (2015) Elizabeth Buchbinder et al. JOURNAL OF CLINICAL INVESTIGATION
- Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
- (2015) John R. Mackey et al. JOURNAL OF CLINICAL ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
- (2015) Christopher R. Heery et al. JAMA Oncology
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
- (2014) V. Tiriveedhi et al. CLINICAL CANCER RESEARCH
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Local tumour hyperthermia as immunotherapy for metastatic cancer
- (2014) Seiko Toraya-Brown et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
- (2014) Elham Fakhrejahani et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses
- (2014) Thomas Kieber-Emmons et al. Frontiers in Immunology
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
- (2013) D. W. Miles et al. ANNALS OF ONCOLOGY
- Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
- (2013) David M. Hyams et al. INVESTIGATIONAL NEW DRUGS
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
- (2013) Claudia Marcela Diaz-Montero et al. Journal of Translational Medicine
- Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial
- (2013) Nuhad K. Ibrahim et al. Journal of Cancer
- Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells
- (2012) Venkataswarup Tiriveedhi et al. BREAST CANCER RESEARCH AND TREATMENT
- MUC1 immunotherapy is here to stay
- (2012) Takashi Kimura et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Human Telomerase Reverse Transcriptase (hTERT) Is a Novel Target of the Wnt/β-Catenin Pathway in Human Cancer
- (2012) Yong Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
- (2011) Federica Cuppone et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
- (2010) Katalin Boér et al. INVESTIGATIONAL NEW DRUGS
- Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
- (2010) Håkan Norell et al. Journal of Translational Medicine
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
- (2010) S. K. Taylor et al. ONCOLOGIST
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients
- (2009) Mark G. Carmichael et al. CANCER
- Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials
- (2009) Jae-Bok Lee et al. INVESTIGATIONAL NEW DRUGS
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence
- (2008) Jarrod P. Holmes et al. CANCER
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started